Clinical trials · New York
ER Positive Breast Cancer clinical trials in New York
We’re tracking 55 recruiting er positive breast cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Brooklyn, New YorkAges 18 years+ - NCT06590857RecruitingPhase 1/Phase 2
Study of targeted radiation for advanced breast cancer
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
Buffalo, New YorkAges Any age - NCT07768436RecruitingPhase 2
cmf chemotherapy for breast cancer in older adults
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
Uniondale, New YorkAges 70 years+ - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT07483307RecruitingPhase 2
Hormone therapy before surgery for lobular breast cancer
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
New York, New YorkAges 50 years+ - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Amsterdam, New YorkAges 18–55 - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Babylon, New YorkAges 18 years+ - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-low breast cancer
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
East Patchogue, New YorkAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
New York, New YorkAges 18 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Rochester, New YorkAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Brooklyn, New YorkAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
New York, New YorkAges 18 years+ - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
New York, New YorkAges 18 years+ - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
The Bronx, New YorkAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
The Bronx, New YorkAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
Stony Brook, New YorkAges 18 years+ - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
New York, New YorkAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Staten Island, New YorkAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Brooklyn, New YorkAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Babylon, New YorkAges 18 years+ - NCT06072807RecruitingPhase 4
Brain imaging study for ER+ breast cancer with brain tumors
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
New York, New YorkAges 18 years+ - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+
ER Positive Breast Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting er positive breast cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 5 studies
- NYU Langone Health · 5 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Mount Sinai West · 4 studies
- Roswell Park Comprehensive Cancer Center · 4 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 3 studies
- Montefiore Medical Center · 3 studies
What taking part in a er positive breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
ER Positive Breast Cancer trials in other states
Common questions
- Are there er positive breast cancer clinical trials in New York?
- Yes. We're currently tracking 55 recruiting er positive breast cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a er positive breast cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a er positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New er positive breast cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.